Year: 2018
Type: editorial
Abstract: The advent of adverse outcome pathways (AOPs) has provided a new lexicon for description of mechanistic toxicology, and a renewed enthusiasm for exploring modes of action resulting in adverse health and environmental effects. In addition, AOPs have been used successfully as a framework for the design and development of non-animal approaches to toxicity testing. Although the value of AOPs is widely recognised, there remain challenges and opportunities associated with their use in practise. The purpose of this article is to consider specifically how the future trajectory of AOPs may provide a basis for addressing some of those challenges and opportunities.
Source: Archives of Toxicology
Institutions: National Centre for the Replacement Refinement and Reduction of Animals in Research, GlaxoSmithKline (United Kingdom), Syngenta (United Kingdom), University of Plymouth, Public Health England, Procter & Gamble (United Kingdom), Unilever (United Kingdom), Shell (United Kingdom), University of Manchester
Language: English
Subfield: Small Animals
Field: Veterinary
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,690
OpenAlex ID: W2793093451